Plasma Heparin Cofactor II Helps Predict Early-Stage Diabetic Kidney Disease

A new study has discovered that patients with diabetes, the plasma heparin cofactor II or HCII activity is inversely correlated with glomerular injury and may serve as a biomarker for early-stage diabetic kidney disease or DKD.

Photo: Diabetic Kidney Disease | InStyleHealth


Experts enrolled 310 Japanese diabetes mellitus patients, from whom plasma HCII activity was assessed using the appropriate assays. The other biochemical markers evaluated included albumin and liver-type fatty acid-binding protein or L-FABP, which were then used to obtain the urine albumin-to-creatinine (uACR) and L-FABP-to-creatinine (uL-FABPCR) ratios.

Mean plasma HCII activity in the overall sample was 93.8% and showed significant associations with serum and plasma markers such as fibrinogen, uACR, and log-transformed.

Using multivariate regression analysis revealed that plasma HCII activity was a significant and independent protective factor against increasing uACR and log-transformed uACR. There was no such effect reported for uL-FABPCR. Being male was similarly significantly inversely associate with uACR and log-transformed uACR, but also with uL-FABPCR.

On the other hand, systolic blood pressure, glycated hemoglobin, and creatinine were positively and significantly correlated with all three urinary biomarkers.

Researchers said that the data generated in this study demonstrated that the plasma HCII activity served as a negative clinical factor for albuminuria development in patient with diabetes. Measuring the plasma HCII activity might enable the prediction and/or development of glomerular disease in patients with DKD at an early stage.

 

Source: J Diabetes Investig 2021;doi:10.1111/jdi.13602

If you have any suggestions, please let us know.

Post a Comment (0)
Previous Post Next Post